Grandfield & Dodd Decreased Dominion Energy (D) Holding By $683,883; Theravance Biopharma Has 1.31 Sentiment

May 18, 2018 - By Vivian Park

Theravance Biopharma, Inc. (NASDAQ:TBPH) Logo

Theravance Biopharma (TBPH) investors sentiment decreased to 1.31 in 2017 Q4. It’s down -0.01, from 1.32 in 2017Q3. The ratio fall, as 38 investment managers opened new or increased equity positions, while 29 decreased and sold equity positions in Theravance Biopharma. The investment managers in our database now hold: 35.06 million shares, down from 35.46 million shares in 2017Q3. Also, the number of investment managers holding Theravance Biopharma in top ten equity positions decreased from 3 to 1 for a decrease of 2. Sold All: 7 Reduced: 22 Increased: 26 New Position: 12.

Grandfield & Dodd Llc decreased Dominion Energy Inc (D) stake by 40.43% reported in 2017Q4 SEC filing. Grandfield & Dodd Llc sold 8,443 shares as Dominion Energy Inc (D)’s stock declined 13.95%. The Grandfield & Dodd Llc holds 12,440 shares with $1.01M value, down from 20,883 last quarter. Dominion Energy Inc now has $41.24B valuation. The stock decreased 0.77% or $0.49 during the last trading session, reaching $63.19. About 750,243 shares traded. Dominion Energy, Inc. (NYSE:D) has declined 11.17% since May 18, 2017 and is downtrending. It has underperformed by 22.72% the S&P500.

Since February 28, 2018, it had 2 insider purchases, and 0 sales for $453,739 activity. $199,987 worth of stock was bought by RIGBY JOSEPH M on Wednesday, February 28. 4,000 Dominion Energy, Inc. (NYSE:D) shares with value of $253,752 were bought by FARRELL THOMAS F II.

Among 21 analysts covering Dominion Midstream (NYSE:D), 8 have Buy rating, 1 Sell and 12 Hold. Therefore 38% are positive. Dominion Midstream had 47 analyst reports since July 23, 2015 according to SRatingsIntel. The stock of Dominion Energy, Inc. (NYSE:D) earned “Overweight” rating by Barclays Capital on Thursday, February 4. The stock of Dominion Energy, Inc. (NYSE:D) has “Outperform” rating given on Tuesday, November 3 by RBC Capital Markets. Deutsche Bank maintained the stock with “Hold” rating in Tuesday, August 25 report. The stock of Dominion Energy, Inc. (NYSE:D) earned “Outperform” rating by Credit Suisse on Wednesday, January 25. On Wednesday, October 18 the stock rating was maintained by KeyBanc Capital Markets with “Hold”. Guggenheim maintained Dominion Energy, Inc. (NYSE:D) on Tuesday, January 2 with “Buy” rating. Morgan Stanley maintained Dominion Energy, Inc. (NYSE:D) on Wednesday, December 13 with “Equal-Weight” rating. RBC Capital Markets maintained Dominion Energy, Inc. (NYSE:D) on Sunday, September 24 with “Hold” rating. Guggenheim maintained Dominion Energy, Inc. (NYSE:D) on Sunday, April 22 with “Buy” rating. The firm has “Hold” rating by RBC Capital Markets given on Friday, June 2.

Analysts await Dominion Energy, Inc. (NYSE:D) to report earnings on August, 1. They expect $0.75 earnings per share, up 11.94% or $0.08 from last year’s $0.67 per share. D’s profit will be $489.42M for 21.06 P/E if the $0.75 EPS becomes a reality. After $1.14 actual earnings per share reported by Dominion Energy, Inc. for the previous quarter, Wall Street now forecasts -34.21% negative EPS growth.

Grandfield & Dodd Llc increased Cognizant Technology Solutio (NASDAQ:CTSH) stake by 8,015 shares to 77,695 valued at $5.52 million in 2017Q4. It also upped Johnson Ctls Intl Plc stake by 25,847 shares and now owns 466,630 shares. Gilead Sciences Inc (NASDAQ:GILD) was raised too.

More recent Dominion Energy, Inc. (NYSE:D) news were published by: Seekingalpha.com which released: “Recent Purchase: Dominion Energy” on May 18, 2018. Also Seekingalpha.com published the news titled: “Protecting Your Dominion Energy Position” on May 14, 2018. Bizjournals.com‘s news article titled: “FERC lets Atlantic Coast Pipeline construction begin in West Virginia” with publication date: May 14, 2018 was also an interesting one.

Investors sentiment increased to 1.32 in Q4 2017. Its up 0.16, from 1.16 in 2017Q3. It improved, as 41 investors sold D shares while 278 reduced holdings. 86 funds opened positions while 336 raised stakes. 415.15 million shares or 1.17% more from 410.35 million shares in 2017Q3 were reported. Webster Bancorporation N A owns 10,057 shares. Blb&B Advisors Ltd Limited Liability Company has 10,843 shares. 8,048 are held by Kcm Advsr Limited Liability. Teacher Retirement Of Texas accumulated 352,054 shares. Sheets Smith Wealth has 3,161 shares for 0.06% of their portfolio. Jpmorgan Chase holds 0.02% or 1.20M shares in its portfolio. Alps holds 76,748 shares. Moreover, Arizona State Retirement Sys has 0.15% invested in Dominion Energy, Inc. (NYSE:D) for 189,428 shares. The California-based Shelton Mngmt has invested 0.02% in Dominion Energy, Inc. (NYSE:D). Moreover, Signature Financial Management Inc has 0.09% invested in Dominion Energy, Inc. (NYSE:D) for 4,198 shares. Moreover, North American Mgmt has 0.23% invested in Dominion Energy, Inc. (NYSE:D) for 18,440 shares. Norris Perne & French Ltd Liability Partnership Mi owns 4,222 shares. Sandy Spring National Bank & Trust stated it has 21,929 shares. Pinebridge Limited Partnership accumulated 4,630 shares. First Midwest Savings Bank Trust Division stated it has 21,222 shares or 0.21% of all its holdings.

Ratings analysis reveals 50% of Theravance Biopharma’s analysts are positive. Out of 2 Wall Street analysts rating Theravance Biopharma, 1 give it “Buy”, 1 “Sell” rating, while 0 recommend “Hold”. The lowest target is $24.0 while the high is $40.0. The stock’s average target of $32 is 31.31% above today’s ($24.37) share price. TBPH was included in 2 notes of analysts from October 12, 2016. The rating was initiated by Needham with “Buy” on Wednesday, December 21. Robert W. Baird downgraded the stock to “Underperform” rating in Wednesday, October 12 report.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company has market cap of $1.34 billion. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. It currently has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

Analysts await Theravance Biopharma, Inc. (NASDAQ:TBPH) to report earnings on August, 14. They expect $-1.24 EPS, up 2.36% or $0.03 from last year’s $-1.27 per share. After $-1.22 actual EPS reported by Theravance Biopharma, Inc. for the previous quarter, Wall Street now forecasts 1.64% negative EPS growth.

Foundation Asset Management Lp holds 3.63% of its portfolio in Theravance Biopharma, Inc. for 432,532 shares. Cormorant Asset Management Llc owns 900,000 shares or 2.63% of their US portfolio. Moreover, Baupost Group Llc Ma has 2.57% invested in the company for 9.31 million shares. The California-based Old West Investment Management Llc has invested 1.81% in the stock. Senzar Asset Management Llc, a New York-based fund reported 171,800 shares.

Dominion Energy, Inc. (NYSE:D) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>